BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35008475)

  • 1. Mutation Analysis of Radioresistant Early-Stage Cervical Cancer.
    Oike T; Sekiguchi Y; Yoshimoto Y; Oike T; Ando K; Gu W; Sasaki Y; Tokino T; Iwase A; Ohno T
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
    Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
    Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.
    Nuryadi E; Sasaki Y; Hagiwara Y; Permata TBM; Sato H; Komatsu S; Yoshimoto Y; Murata K; Ando K; Kubo N; Okonogi N; Takakusagi Y; Adachi A; Iwanaga M; Tsuchida K; Tamaki T; Noda SE; Hirota Y; Shibata A; Ohno T; Tokino T; Oike T; Nakano T
    Oncotarget; 2018 Aug; 9(66):32642-32652. PubMed ID: 30220971
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wang F; Xia X; Yang C; Shen J; Mai J; Kim HC; Kirui D; Kang Y; Fleming JB; Koay EJ; Mitra S; Ferrari M; Shen H
    Clin Cancer Res; 2018 Jul; 24(13):3176-3185. PubMed ID: 29602802
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Sideris M; Moorhead J; Diaz-Cano S; Haji A; Papagrigoriadis S
    Anticancer Res; 2017 Mar; 37(3):1349-1357. PubMed ID: 28314302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
    Hammarström K; Nunes L; Mathot L; Mezheyeuski A; Lundin E; Korsavidou Hult N; Imam I; Osterlund E; Sjöblom T; Glimelius B
    Int J Cancer; 2024 Jul; 155(1):40-53. PubMed ID: 38376070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.
    Yang L; Shen C; Estrada-Bernal A; Robb R; Chatterjee M; Sebastian N; Webb A; Mo X; Chen W; Krishnan S; Williams TM
    Nucleic Acids Res; 2021 Nov; 49(19):11067-11082. PubMed ID: 34606602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.
    Baldelli E; Bellezza G; Haura EB; Crinó L; Cress WD; Deng J; Ludovini V; Sidoni A; Schabath MB; Puma F; Vannucci J; Siggillino A; Liotta LA; Petricoin EF; Pierobon M
    Oncotarget; 2015 Oct; 6(32):32368-79. PubMed ID: 26468985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients.
    Sharmin S; Zohura FT; Islam MS; Shimonty A; Khan MA; Parveen R; Sharmin F; Ahsan CR; Islam ABMMK; Yasmin M
    BMC Cancer; 2021 Mar; 21(1):289. PubMed ID: 33736612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutational analysis of KRAS and its clinical implications in cervical cancer patients.
    Jiang W; Xiang L; Pei X; He T; Shen X; Wu X; Yang H
    J Gynecol Oncol; 2018 Jan; 29(1):e4. PubMed ID: 29185262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: A case-control study.
    Liao X; Hao Y; Zhang X; Ward S; Houldsworth J; Polydorides AD; Harpaz N
    PLoS One; 2019; 14(2):e0212142. PubMed ID: 30730996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotype of mutant ras p21 and early response to radiotherapy in cancer of the uterine cervix.
    Sreelekha TT; Nair MK; Jayaprakash PG; Pillai MR
    J Exp Clin Cancer Res; 1999 Sep; 18(3):337-41. PubMed ID: 10606179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
    Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
    Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
    Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
    Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis.
    Leung L; Radulovich N; Zhu CQ; Wang D; To C; Ibrahimov E; Tsao MS
    PLoS One; 2013; 8(12):e84366. PubMed ID: 24386371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.